1. Home
  2. INCY
  3. INCY News

Latest Incyte Corp. (INCY) News on October 25, 2025

Incyte (INCY) Earnings Expected to Grow: Should You Buy?
INCY

Zacks

3 days ago

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Incyte's Quarterly Earnings Preview: What You Need to Know
INCY

Barchart

4 days ago

Incyte's Quarterly Earnings Preview: What You Need to Know

Assessing Incyte’s Share Price After Recent FDA Approval and Strong 2024 Gains
INCY

Simply Wall St.

4 days ago

Assessing Incyte’s Share Price After Recent FDA Approval and Strong 2024 Gains

Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice
INCY

Zacks

4 days ago

Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice

INCY

MT Newswires

5 days ago

BMO Capital Adjusts Price Target on Incyte to $75 From $60, Maintains Underperform Rating

INCY

MT Newswires

5 days ago

Incyte's Potential Colorectal, Pancreatic Cancer Treatments Merit 'Continued Clinical Development'

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
INCY

Business Wire

5 days ago

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
INCY

Business Wire

12 days ago

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

INCY

MT Newswires

19 days ago

Maze Therapeutics Appoints Herve Hoppenot as Board Chairman

Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism
INCY

Insider Monkey

23 days ago

Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism

2 Reasons to Like INCY and 1 to Stay Skeptical
INCY

StockStory

23 days ago

2 Reasons to Like INCY and 1 to Stay Skeptical

INCY vs. ARGX: Which Stock Is the Better Value Option?
INCY

Zacks

24 days ago

INCY vs. ARGX: Which Stock Is the Better Value Option?

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
INCY

Business Wire

a month ago

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval
INCY

Simply Wall St.

a month ago

How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
INCY

Zacks

a month ago

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream

INCY

MT Newswires

a month ago

Jefferies Adjusts Price Target on Incyte to $102 From $90, Maintains Buy Rating

INCY

MT Newswires

a month ago

Incyte Gets FDA Approval for Opzelura in Children Aged 2 to 11

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
INCY

Business Wire

a month ago

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

INCY

MT Newswires

a month ago

Incyte Reports Positive Data for Hidradenitis Suppurativa Treatment

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
INCY

Business Wire

a month ago

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Alger Russell Innovation Index Updates for Third Quarter 2025
INCY

PR Newswire

a month ago

Alger Russell Innovation Index Updates for Third Quarter 2025

Incyte Corporation (INCY) Advances KRAS Cancer Program
INCY

Insider Monkey

a month ago

Incyte Corporation (INCY) Advances KRAS Cancer Program

Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% Rally
INCY

Investor's Business Daily

2 months ago

Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% Rally

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?
INCY

Zacks

2 months ago

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
INCY

Business Wire

2 months ago

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte (INCY) Stock Is Up, What You Need To Know
INCY

StockStory

2 months ago

Incyte (INCY) Stock Is Up, What You Need To Know

Large-cap biotech is a sector to watch for investors: Analysts
INCY

Yahoo Finance

2 months ago

Large-cap biotech is a sector to watch for investors: Analysts

Did Incyte's (INCY) Leadership Shift and Pipeline Milestones Just Reshape Its Investment Narrative?
INCY

Simply Wall St.

2 months ago

Did Incyte's (INCY) Leadership Shift and Pipeline Milestones Just Reshape Its Investment Narrative?

Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?
INCY

Zacks

2 months ago

Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?

Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership
INCY

Insider Monkey

2 months ago

Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

2 months ago

JPMorgan Adjusts Price Target on Incyte to $73 From $67, Maintains Neutral Rating

2 Mooning Stocks with Exciting Potential and 1 We Ignore
INCY

StockStory

2 months ago

2 Mooning Stocks with Exciting Potential and 1 We Ignore

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
INCY

Zacks

2 months ago

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?
INCY

Barchart

2 months ago

Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?

Cytokinetics Names Jim Daly to Board of Directors
INCY

GlobeNewswire

2 months ago

Cytokinetics Names Jim Daly to Board of Directors

Incyte to Present at Upcoming Investor Conferences
INCY

Business Wire

2 months ago

Incyte to Present at Upcoming Investor Conferences

Incyte Stock Gets Relative Strength Rating Lift
INCY

Investor's Business Daily

4 months ago

Incyte Stock Gets Relative Strength Rating Lift

Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz
INCY

TipRanks

4 months ago

Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
INCY

Investor's Business Daily

4 months ago

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
INCY

Investor's Business Daily

4 months ago

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY

Business Wire

4 months ago

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
INCY

Barchart

4 months ago

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

FDA Extends INCY's Application for Opzelura Label Expansion
INCY

Zacks

4 months ago

FDA Extends INCY's Application for Opzelura Label Expansion

5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call
INCY

StockStory

4 months ago

5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
INCY

StockStory

4 months ago

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

INCY

MT Newswires

4 months ago

Incyte Says FDA Extends Review Period for Ruxolitinib Cream

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
INCY

Business Wire

4 months ago

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
INCY

Insider Monkey

4 months ago

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
INCY

Zacks

4 months ago

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

INCY

MT Newswires

4 months ago

Incyte's Drug to Treat Follicular Lymphoma Receives FDA Approval

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY

Business Wire

4 months ago

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value
INCY

Simply Wall St.

4 months ago

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY

Zacks

4 months ago

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
INCY

TipRanks

4 months ago

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls

3 Unpopular Stocks in Hot Water
INCY

StockStory

4 months ago

3 Unpopular Stocks in Hot Water

INCY

MT Newswires

4 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

QGEN Stock Rises in After Market Following Partnership With Incyte
INCY

Zacks

4 months ago

QGEN Stock Rises in After Market Following Partnership With Incyte

Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms
INCY

Medical Device Network

4 months ago

Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms

INCY

MT Newswires

4 months ago

Stifel Upgrades Incyte to Buy From Hold, Adjusts Price Target to $107 From $75

INCY

MT Newswires

4 months ago

Jefferies Adjusts Price Target on Incyte to $82 From $76, Maintains Buy Rating

INCY

MT Newswires

4 months ago

QIAGEN, Incyte Partner to Develop NGS-Based Diagnostic Panel for Rare Blood Cancers

INCY

MT Newswires

4 months ago

Incyte Says 86% of Blood Cancer Patients Responsive to Higher Doses of Drug Candidate

Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
INCY

Insider Monkey

4 months ago

Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
INCY

Business Wire

4 months ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY

Business Wire

4 months ago

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Specialised Therapeutics announces expanded partnership with Incyte
INCY

TipRanks

4 months ago

Specialised Therapeutics announces expanded partnership with Incyte

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY

Business Wire

4 months ago

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

5 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
INCY

Zacks

5 months ago

Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
INCY

Zacks

5 months ago

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?

US High Growth Tech Stocks To Watch In June 2025
INCY

Simply Wall St.

5 months ago

US High Growth Tech Stocks To Watch In June 2025

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
INCY

Business Wire

5 months ago

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

INCY

Morningstar Research

5 months ago

Analyst Report: Incyte Corporation

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
INCY

Zacks

5 months ago

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

5 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

5 months ago

Truist Securities Adjusts Price Target on Incyte to $73 From $72, Maintains Hold Rating

3 Reasons INCY is Risky and 1 Stock to Buy Instead
INCY

StockStory

5 months ago

3 Reasons INCY is Risky and 1 Stock to Buy Instead

3 Mid-Cap Stocks with Questionable Fundamentals
INCY

StockStory

5 months ago

3 Mid-Cap Stocks with Questionable Fundamentals

FDA approves Incyte’s retifanlimab combo for SCAC treatment
INCY

Pharmaceutical Technology

5 months ago

FDA approves Incyte’s retifanlimab combo for SCAC treatment

Incyte Gets FDA Approval for Zynyz in New Cancer Indication
INCY

Zacks

5 months ago

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

INCY

MT Newswires

5 months ago

Leerink Partners Adjusts Incyte Price Target to $96 From $95

INCY

MT Newswires

5 months ago

Incyte Says FDA Approves Zynyz for Anal Cancer Treatment

INCY

MT Newswires

5 months ago

Argus Lowers Price Target on Incyte to $75 From $80

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
INCY

Business Wire

5 months ago

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

INCY

Argus Research

5 months ago

Analyst Report: Incyte Corp.

INCY

Argus Research

5 months ago

Market Update: CSCO, FCX, INCY, XRX, SMCI

INCY

MT Newswires

5 months ago

Incyte to Pay Novartis $280 Million to Resolve Jakafi Royalties Dispute

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
INCY

Insider Monkey

5 months ago

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
INCY

StockStory

5 months ago

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

6 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What To Expect From Natera’s (NTRA) Q1 Earnings
INCY

StockStory

6 months ago

What To Expect From Natera’s (NTRA) Q1 Earnings

INCY

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Syndax Pharmaceuticals Inc Earnings Call

INCY

MT Newswires

6 months ago

Mizuho Adjusts Price Target on Incyte to $70 From $77, Maintains Neutral Rating

High Growth Tech Stocks in US with Strong Potential for Investors
INCY

Simply Wall St.

6 months ago

High Growth Tech Stocks in US with Strong Potential for Investors

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

6 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

6 months ago

Leerink Partners Raises Price Target on Incyte to $95 From $92

INCY

MT Newswires

6 months ago

Stifel Lowers Price Target on Incyte to $75 From $77

INCY

MT Newswires

6 months ago

TD Cowen Lowers Price Target on Incyte to $86 From $88

INCY

MT Newswires

6 months ago

Morgan Stanley Adjusts Incyte's Price Target to $68 From $65

Share on Social Networks: